163 related articles for article (PubMed ID: 11441984)
1. Tissue factor pathway inhibitor release induced by defibrotide and heparins.
Cella G; Sbarai A; Mazzaro G; Motta G; Carraro P; Andreozzi GM; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2001 Jul; 7(3):225-8. PubMed ID: 11441984
[TBL] [Abstract][Full Text] [Related]
2. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
3. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
4. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Naumnik B; Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
[TBL] [Abstract][Full Text] [Related]
5. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
9. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
10. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
Hoppensteadt DA; Jeske W; Fareed J; Nicolaides AN
Int Angiol; 1996 Mar; 15(1):39-46. PubMed ID: 8739535
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
[TBL] [Abstract][Full Text] [Related]
13. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
14. Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.
Hansen JB; Svensson B; Sandset PM; Thijssen F
Thromb Res; 2000 Dec; 100(5):389-96. PubMed ID: 11150580
[TBL] [Abstract][Full Text] [Related]
15. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
16. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.
Hansen JB; Svensson B; Olsen R; Ezban M; Osterud B; Paulssen RH
Thromb Haemost; 2000 Jun; 83(6):937-43. PubMed ID: 10896252
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
18. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
[TBL] [Abstract][Full Text] [Related]
19. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
20. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
Sandset PM; Bendz B; Hansen JB
Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
